Cédrickx Godbout

This inventor holds 23 USPTO granted patents and 17 published patent applications and 13 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Cédrickx Godbout. Retrieved from https://idiyas.com/inventor/cedrickx-godbout

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 23 (Patent Applications = 17)

% Patents Active = 100.0

EPO Patents = 13 (Patent Applications = 24)

Average Co-Inventor Count = 4.6

ph-index = 2

Forward Citations = 15(Granted Patents)

Location History:

Laval, CA (2013 - 2014)
Attenweiler, DE (2016 - 2024)

Company Filing History:

23 out of 1,564

Boehringer Ingelheim International Gmbh

patents

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

cGAS Inhibitors

GOAT Inhibitors

Vanin Inhibitors

Heteroaromatic Compounds

Oxadiazolopyridine Derivatives

Viral Polymerase Inhibitors

Pyridine Derivatives

Heterocyclic Compounds

Inflammatory Diseases

Fibrotic Diseases

Pharmaceutical Compositions

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12433897 - Pyridine derivatives with n-linked cyclic substituents as cGAS inhibitors (2025-10-07),

2. 12391667 - N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases (2025-08-19),

3. 12358910 - Heteroaromatic compounds as Vanin inhibitors (2025-07-15),

4. 12240828 - Heteroaromatic compounds as vanin inhibitors (2025-03-04),

5. 12065427 - Heterocyclic compounds capable of activating STING (2024-08-20),

6. 12043625 - Pyridine derivatives with c-linked cyclic substituents as cGAS inhibitors (2024-07-23),

7. RE49446 - Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors (2023-03-06),

8. 11583532 - Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors (2023-02-21),

9. 11485727 - N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators (2022-11-01),

10. 11465982 - Pyridazines (2022-10-11),

11. 11319310 - Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors (2022-05-03),

12. 11254688 - Benzyl-, (pyridin-3-yl)methyl -or (pyridin-4-yl)-methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors (2022-02-22),

13. 11136337 - Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors (2021-10-05),

14. 11078182 - Heteroaromatic compounds as Vanin inhibitors (2021-08-03),

15. 10864201 - Heteroaromatic compounds as Vanin inhibitors (2020-12-15),

Title: The Innovative Mind of Cédrickx Godbout

Introduction: Cédrickx Godbout, a talented inventor hailing from Attenweiler, Germany, is known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Cédrickx Godbout holds several patents in the areas of artificial intelligence, renewable energy, and sustainable transportation, showcasing his diverse range of expertise and forward-thinking approach to problem-solving.

Career Highlights: With a career spanning over two decades, Cédrickx Godbout has worked with leading tech companies and research institutions, spearheading projects that have revolutionized industries and improved the quality of life for many.

Collaborations: Throughout his career, Cédrickx Godbout has collaborated with top engineers, scientists, and designers from around the world, fostering a culture of innovation and creativity that has led to numerous successful projects and inventions.

Conclusion: Cédrickx Godbout's passion for innovation, coupled with his relentless drive to push the boundaries of what is possible, has solidified his reputation as a visionary inventor in the global tech community.

Profile summary based on public USPTO records.